Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)
Status:
Withdrawn
Trial end date:
2021-05-14
Target enrollment:
Participant gender:
Summary
Intracerebral hemorrhage (ICH) is responsible for 10-15% of primary strokes. ICH is a dynamic
process with three phases: initial hemorrhage, followed by hematoma expansion and
perihematoma edema formation. Hematoma volume is correlated with disease progression and
outcome. Contemporary evidence proposes that elevated blood pressure is associated with
hematoma expansion while more than 90% of patients with ICH present with acute hypertension.
Uncontrolled blood pressure is a leading cause of ICH and it seems also to be a factor of
poorer outcomes. Therefore, rapid reduction and control of blood pressure might ease disease
progression and improve the outcome. Clevidipine (Cleviprex®), an ultrashort-acting
dihydropyridine calcium channel antagonist, with its rapid onset and short duration might be
more effective than conventional antihypertensives to achieve rapid blood pressure control in
patients with acute ICH.